Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma.
Sarcomas are a heterogeneous group of mesenchymal malignancies. In recent years, studies have demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of sarcomas. However, when used as monotherapy in the clinical setting, these targeted antiangiogenic agents have only provided modest survival benefits in some sarcoma subtypes, and have not been efficacious in others. Preclinical and early clinical data suggest that the addition of conventional chemotherapy to antiangiogenic agents may lead to more effective therapies for patients with these tumors. In the current review, the authors summarize the available evidence and possible mechanisms supporting this approach.
Department of Pediatrics, UCSF School of Medicine, San Francisco School of Medicine, UCSF Benioff Children's Hospital, University of California, 550 16th Street, 4th Floor, Box 0434, San Francisco, CA 94158 USA.
Kieuhoa T
KT
Vo
Department of Pediatrics, UCSF School of Medicine, San Francisco School of Medicine, UCSF Benioff Children's Hospital, University of California, 550 16th Street, 4th Floor, Box 0434, San Francisco, CA 94158 USA.
Katherine K
KK
Matthay
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, 450 Brookline Avenue, Dana 3, Boston, MA 02215 USA.
Steven G
SG
DuBois
Antiangiogenesis; Combination chemotherapy; Combination drug therapy; Sarcoma